Pharmacogenetic Testing Among Patients with Mood and Anxiety Disorders Is Associated with Decreased Utilization and Cost: A Propensity-Score Matched Study
About this Item
Title:
Pharmacogenetic Testing Among Patients with Mood and Anxiety Disorders Is Associated with Decreased Utilization and Cost: A Propensity-Score Matched Study
Naturalistic and small randomized trials have suggested that pharmacogenetic testing may improve treatment outcomes in depression, but its cost-effectiveness is not known. There is growing enthusiasm for personalized medicine, relying on genetic variation as a contributor to heterogeneity of treatment effects. We sought to examine the relationship between a commercial pharmacogenetic test for psychotropic medications and 6-month cost of care and utilization in a large commercial health plan.
